GSA Capital Partners LLP Buys 1,003,135 Shares of Outset Medical, Inc. (NASDAQ:OM)

GSA Capital Partners LLP increased its stake in shares of Outset Medical, Inc. (NASDAQ:OM) by 924.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,111,612 shares of the company’s stock after purchasing an additional 1,003,135 shares during the quarter. GSA Capital Partners LLP’s holdings in Outset Medical were worth $753,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of OM. State Board of Administration of Florida Retirement System lifted its stake in Outset Medical by 33.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 18,842 shares of the company’s stock worth $42,000 after purchasing an additional 4,720 shares during the last quarter. Ground Swell Capital LLC bought a new stake in shares of Outset Medical during the 2nd quarter worth approximately $49,000. Vanguard Personalized Indexing Management LLC purchased a new position in Outset Medical during the 2nd quarter valued at $49,000. Summit Securities Group LLC bought a new position in Outset Medical in the 2nd quarter valued at $105,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Outset Medical by 75.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 82,636 shares of the company’s stock worth $184,000 after purchasing an additional 35,495 shares during the period.

Outset Medical Price Performance

Shares of OM stock opened at $0.79 on Monday. Outset Medical, Inc. has a twelve month low of $0.44 and a twelve month high of $6.37. The company has a current ratio of 6.49, a quick ratio of 5.38 and a debt-to-equity ratio of 4.12. The stock has a fifty day simple moving average of $0.61 and a two-hundred day simple moving average of $2.21. The stock has a market capitalization of $41.61 million, a price-to-earnings ratio of -0.29 and a beta of 1.95.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Royal Bank of Canada lowered shares of Outset Medical from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $6.00 to $3.00 in a research note on Thursday, August 8th. TD Cowen lowered their price objective on shares of Outset Medical from $9.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.70.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.